← Leaderboards
Stanley Wang
Aligos Therapeutics, Inc.
$11,286,393
Attributed
$11,286,393
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $8.5M · FY2023–25$10M$7.5M$5M$2.5M$0
'23
'24
'25
Funding mix
By agency
NIH$11,286,393 · 1
By mechanism
N01$11,286,393 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Advanced Development”
- Kiran Datta · Leidos Biomedical Research, Inc.$277,585,346
- Katherine M Thibault · Battelle Memorial Institute$134,148,552
- Mari Ostendorf · University Of Washington$51,931,230
- Richard Smith · Medical Device Innovation Consortium$41,401,350
- Brian Zavertnik · Palantir Technologies, Inc.$33,059,912
- Cyrus Wadia · Activate Global, Inc.$31,489,493
Research focus
Advanced DevelopmentChemistryCovid-19 TherapeuticsEfficacy EvaluationManufacturePre-ClinicalProduct DevelopmentResearch And DevelopmentSafety AssessmentTherapeutic CandidateEvaluationLead OptimizationResearch SupportPhase I Clinical TrialsViralCandidate SelectionClinical AssessmentsClinical DevelopmentTherapeutic DevelopmentPathway InteractionsHepaticClinical TrialsProgramsImpairment